Main Menu

Professor Andrew Hayes

Group Leader

The alt text
Professor Andrew Hayes is a Surgical Oncologist specialising in the surgery of soft tissue sarcomas, malignant melanoma and other rare tumours of the skin and soft tissues. He is Head of the Skin Unit and Clinical Director for the Rare Cancers Clinical Business Unit at The Royal Marsden NHS Foundation Trust. Group: Sarcoma and Melanoma Surgery
+44 20 7153 5157


Professor Hayes is a Consultant General Surgeon and Surgical Oncologist at the Sarcoma Unit and the Skin Unit at The Royal Marsden and an Honorary Faculty at the ICR since October 2017.

His pre-clinical training was at Oxford University and his clinical training was at St Bartholomew’s Hospital, London. He undertook his postgraduate surgical training in London. Professor Hayes spent three years of research training at the Lombardi Cancer Center, Georgetown University Hospital, Washington DC, US, for which he was awarded a PhD in 2001. In 2002, Professor Hayes was awarded a Hunterian Professorship by the Royal College of Surgeons in England for his research into angiogenesis as a therapeutic approach for cancer.

For the last 14 years, Professor Hayes has developed a specialist surgical practice in soft-tissue sarcoma and advanced melanoma. He leads the Isolated Limb Perfusion programme, which provides a national service for regional chemotherapy for patients with advanced limb malignancy. He is currently the Lead Clinician of The Royal Marsden’s Skin Unit as well as Clinical Director of the Rare Cancers Clinical Business Unit, and Co-Chair of the London and South East England Sarcoma Advisory Group.

Professor Hayes has published widely on clinical aspects of sarcoma and melanoma, culminating most recently in publication of the long-term results of a multinational randomised trial of surgical margins in primary melanoma. For the last eight years, Professor Hayes has also been running a translational research programme in the ICR developing new therapeutic agents to be delivered alongside standard chemotherapy by isolated limb perfusion for the treatment of advanced irresectable limb malignancies.

Professor Hayes gained the title of Reader at the ICR in 2019 and was conferred with the title of Professor in 2022.

Image of Professor Hayes above courtesy of The Royal Marsden.